These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26950303)

  • 1. Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries.
    Abad R; Medina V; Stella M; Boccadifuoco G; Comanducci M; Bambini S; Muzzi A; Vázquez JA
    PLoS One; 2016; 11(3):e0150721. PubMed ID: 26950303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland.
    Waśko I; Hong E; De Paola R; Stella M; Moschioni M; Taha MK; Skoczyńska A
    Vaccine; 2016 Jan; 34(4):510-515. PubMed ID: 26686998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.
    Law DK; Lefebvre B; Gilca R; Deng S; Zhou J; De Wals P; Tsang RS
    BMC Microbiol; 2015 Jul; 15():143. PubMed ID: 26204985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
    Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
    Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.
    Abad R; Biolchi A; Moschioni M; Giuliani MM; Pizza M; Vázquez JA
    Clin Vaccine Immunol; 2015 Apr; 22(4):357-60. PubMed ID: 25630407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meningococcal Antigen Typing System (MATS)-Based
    Rajam G; Stella M; Kim E; Paulos S; Boccadifuoco G; Serino L; Carlone G; Medini D
    mSphere; 2017; 2(6):. PubMed ID: 29152576
    [No Abstract]   [Full Text] [Related]  

  • 10. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine.
    Tzanakaki G; Hong E; Kesanopoulos K; Xirogianni A; Bambini S; Orlandi L; Comanducci M; Muzzi A; Taha MK
    BMC Microbiol; 2014 Apr; 14():111. PubMed ID: 24779381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.
    Bodini M; Brozzi A; Giuliani M; Nohynek H; Vainio A; Kuusi M; De Paola R; Pizza M; Medini D; Toropainen M; Serino L; Muzzi A
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal.
    Simões MJ; Bettencourt C; De Paola R; Giuliani M; Pizza M; Moschioni M; Machado J
    PLoS One; 2017; 12(5):e0176177. PubMed ID: 28459837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp).
    Abad R; García-Amil C; Navarro C; Martín E; Martín-Díaz A; Vázquez JA
    J Infect; 2021 Apr; 82(4):37-44. PubMed ID: 33610688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
    Medini D; Stella M; Wassil J
    Vaccine; 2015 May; 33(23):2629-36. PubMed ID: 25882169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines.
    Plikaytis BD; Stella M; Boccadifuoco G; DeTora LM; Agnusdei M; Santini L; Brunelli B; Orlandi L; Simmini I; Giuliani M; Ledroit M; Hong E; Taha MK; Ellie K; Rajam G; Carlone GM; Claus H; Vogel U; Borrow R; Findlow J; Gilchrist S; Stefanelli P; Fazio C; Carannante A; Oksnes J; Fritzsønn E; Klem AM; Caugant DA; Abad R; Vázquez JA; Rappuoli R; Pizza M; Donnelly JJ; Medini D
    Clin Vaccine Immunol; 2012 Oct; 19(10):1609-17. PubMed ID: 22875603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variability of Polish serogroup B meningococci (2010-2016) including the 4CMenB vaccine component genes.
    Waśko I; Gołębiewska A; Kiedrowska M; Ronkiewicz P; Wróbel-Pawelczyk I; Kuch A; Hong E; Skoczyńska A
    Vaccine; 2020 Feb; 38(8):1943-1952. PubMed ID: 31980191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway.
    Holst J; Comanducci M; Bambini S; Muzzi A; Comandi S; Oksnes J; DeTora L; Pizza M; Rappuoli R; Caugant DA
    Vaccine; 2014 May; 32(23):2722-31. PubMed ID: 24631075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.
    Pérez-Trallero E; Esnal O; Marimón JM
    PLoS One; 2014; 9(12):e116024. PubMed ID: 25541709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020.
    Muzzi A; Lu M-C; Mori E; Biolchi A; Fu T; Serino L
    mSphere; 2024 Jun; 9(6):e0022024. PubMed ID: 38752729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.